SRI Biosciences delivers next-generation drugs, diagnostics and devices to solve unmet medical needs. We work with partners to develop transformative approaches and platforms for the toughest therapeutic problems.
Our innovation strategies are built on more than 50 years of drug development and discovery experience. We’ve refined our ability to repeat biomedical discovery and catalyze innovation into new products.
Ian M. Colrain
President, Biosciences Division
Some of our innovators
Massimiliano de Zambotti
Research Scientist, Human Sleep Research Program, Center for Health Sciences
Targeted Antigen Loaded Liposomes (TALL)
SRI scientists exploit the human immune response to target cancer cells and extend the benefits of cancer immunotherapies
Research and development December 8, 2020
The mental health impact of COVID-19 restrictions
How did pandemic isolation and pandemic-related changes affect individuals around the globe?
Press release November 23, 2020
SRI awarded $107 million NIAID-DAIDS contract to provide preclinical services for HIV therapeutics
SRI Biosciences will provide a suite of preclinical product development services to support the formulation of potential therapeutic agents
SRI Biosciences’ highly specialized platforms marry the advantages of our cutting-edge research with our flexible biotech business model. Partner with us to leverage our rigorous early discovery and development to customize your specific applications.
FOX Three Molecular Guidance System™
Cell-selective, intracellular delivery of macromolecular therapeutics: Deliver essentially any cargo to selected cell types, and internalize into those cells to targeted subcellular locations.
Suite of automated tools leverages AI to recreate and scale literature-reported synthesis procedures. Solutions focus on key areas of route design, reaction screening and optimization (RSO), and multi-step synthesis development.
AI-guided precision cancer therapy platform provides a new approach to finding targeted therapies for previously “undruggable mutations.”
There are many talented researchers from various disciplines at SRI. This creates an exciting environment and fertile ground for cutting edge research thanks to the cooperation of different teams. This highly effective collaboration allows SRI to invent and develop unique and novel products and technologies.
Research Scientist, Biosciences Division
Featured publicationsSearch publications
Acute Cognitive Effects of the Hypocretin Receptor Antagonist Almorexant Relative to Zolpidem and Placebo: A Randomized Clinical Trial
SRI Authors: Thomas C Neylan, Anne Richards, Thomas J Metzler, Leslie M Ruoff, Jonathan Varbel, Aoife O'Donovan, Melinda Sivasubramanian, Terri Motraghi, Jennifer Hlavin, Steven L Batki , Sabra S Inslicht, Kristin Samuelson, Stephen R Morairty, Thomas Kilduff
Article April 13, 2020
Shallow Metabolic Depression and Human Spaceflight: A Feasible First Step
SRI Authors: Matthew D Regan, Erin E Flynn-Evans, Yuri V Griko, Thomas Kilduff, Jon C Rittenberger, Keith J Ruskin, C Loren Buck
Journal Article March 1, 2020
How can we help?
Once you hit send…
We’ll match your inquiry to the person who can best help you. Expect a response within 48 hours.